Orexo's Partner Gesynta Pharma Announces Positive Results from Phase 1 Study for OX-MPI

Corporate Breaking News

Home : Orexo's Partner Gesynta Pharma Announces Positive Results from Phase 1 Study for OX-MPI

May 15 2020	Orexo's Partner Gesynta Pharma Announces Positive Results from Phase 1 Study for OX-MPI
UPPSALA, Sweden, May 15, 2020 /PRNewswire/ -- Orexo's partner, Gesynta Pharma, today announces positive phase I results for OX-MPI (GS-248). Gesynta Pharma, who owns all the rights to OX-MPI (GS-248), aims to develop a treatment for the microvascular diseases in chronic inflammatory...


Source:https://www.prnewswire.com:443/news-releases/orexos-partner-gesynta-pharma-announces-positive-results-from-phase-1-study-for-ox-mpi-301060007.html

Related News
» Ascentage Pharma to Present Six Abstracts at 2020 AACR Annual Meeting » China XD Plastics Company Limited Special Committee Engages Financial Advisor and Legal Counsel